Real-world studies no substitute for RCTs in establishing efficacy

Published on Jan 1, 2019in The Lancet59.102
· DOI :10.1016/S0140-6736(18)32840-X
Hertzel C. Gerstein93
Estimated H-index: 93
(Population Health Research Institute),
John J.V. McMurray151
Estimated H-index: 151
(Glas.: University of Glasgow),
Rury R. Holman99
Estimated H-index: 99
(University of Oxford)
  • References (10)
  • Citations (14)
📖 Papers frequently viewed together
1 Citations
15 Citations
1 Author (Eric Suba)
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Christopher J. Rush (BHF: British Heart Foundation)H-Index: 4
#2Ross T. Campbell (BHF: British Heart Foundation)H-Index: 12
Last. John J.V. McMurray (BHF: British Heart Foundation)H-Index: 151
view all 5 authors...
Aims: Treatment ‘effects’ are often inferred from non-randomized and observational studies. These studies have inherent biases and limitations, which may make therapeutic inferences based on their results unreliable. We compared the conflicting findings of these studies to those of prospective randomized controlled trials (RCTs) in relation to pharmacological treatments for heart failure (HF). Methods and results: We searched Medline and Embase to identify studies of the association between non-...
12 CitationsSource
#1Jennifer Gill (OHSU: Oregon Health & Science University)H-Index: 3
#2Vinayak PrasadH-Index: 24
8 CitationsSource
#1Matthew A. Cavender (UNC: University of North Carolina at Chapel Hill)H-Index: 21
#2Anna Norhammar (KI: Karolinska Institutet)H-Index: 30
Last. Brian MurphyH-Index: 1
view all 28 authors...
Abstract Background Prior studies found patients treated with sodium-glucose co-transporter-2 inhibitors (SGLT-2i) had lower rates of death and heart failure (HF). Whether the benefits of SGLT-2i vary based upon the presence of cardiovascular disease (CVD) is unknown. Objectives This study sought to determine the association between initiation of SGLT-2i therapy and HF or death in patients with and without CVD. Methods The CVD-REAL (Comparative Effectiveness of Cardiovascular Outcomes in New Use...
21 CitationsSource
#1William T. Cefalu (American Diabetes Association)H-Index: 5
#2Sanjay Kaul (Cedars-Sinai Medical Center)H-Index: 27
Last. Matthew C. Riddle (OHSU: Oregon Health & Science University)H-Index: 54
view all 13 authors...
In December 2008, the U.S. Food and Drug Administration issued guidance to the pharmaceutical industry setting new expectations for the development of antidiabetes drugs for type 2 diabetes. This guidance expanded the scope and cost of research necessary for approval of such drugs by mandating long-term cardiovascular outcomes trials (CVOTs) for safety. Since 2008, 9 CVOTs have been reported, 13 are under way, and 4 have been terminated. Reassuringly, each of the completed trials demonstrated th...
94 CitationsSource
#1Louise Bowman (Medical Research Council)H-Index: 18
#2Marion Mafham (Medical Research Council)H-Index: 9
Last. Jane Armitage (Medical Research Council)H-Index: 50
view all 9 authors...
Objectives The use of aspirin for the secondary prevention of cardiovascular disease (CVD) is firmly established, and the proportional reductions in heart attacks and strokes appear to be similar in people with and without diabetes. Uncertainty remains about the role of antiplatelet treatments for primary prevention of CVD, and guidelines vary in their recommendations. It has also been hypothesized that long-term aspirin can prevent gastro-intestinal and other cancers. Observational studies sugg...
11 CitationsSource
#1Jessica M. Franklin (Harvard University)H-Index: 25
#2Seabastian Schneeweiss (Harvard University)H-Index: 83
Regulators consider randomized controlled trials (RCTs) as the gold standard for evaluating the safety and effectiveness of medications, but their costs, duration, and limited generalizability have caused some to look for alternatives. Real world evidence based on data collected outside of RCTs, such as registries and longitudinal healthcare databases, can sometimes substitute for RCTs, but concerns about validity have limited their impact. Greater reliance on such real world data (RWD) in regul...
25 CitationsSource
#1Tyler J. VanderWeele (Harvard University)H-Index: 57
#2Peng Ding (Harvard University)H-Index: 6
Sensitivity analysis is useful in assessing how robust an association is to potential unmeasured or uncontrolled confounding. This article introduces a new measure called the "E-value," which is related to the evidence for causality in observational studies that are potentially subject to confounding. The E-value is defined as the minimum strength of association, on the risk ratio scale, that an unmeasured confounder would need to have with both the treatment and the outcome to fully explain awa...
293 CitationsSource
#1Autumn DowneyH-Index: 1
#2Amanda Wagner GeeH-Index: 1
Last. Anne B. ClaiborneH-Index: 1
view all 3 authors...
4 CitationsSource
#1Thomas Nyström (KI: Karolinska Institutet)H-Index: 23
#2Johan Bodegard (AstraZeneca)H-Index: 21
Last. Jan W. Eriksson (Uppsala University)H-Index: 26
view all 6 authors...
Abstract Aims The objective of this nationwide study was to compare the risk of all-cause mortality, fatal and nonfatal cardiovascular disease (CVD), and severe hypoglycemia in patients with type 2 diabetes (T2D) on metformin monotherapy treatment starting second-line treatment with either insulin or dipeptidyl peptidase-4 inhibitor (DPP-4i). Methods All patients with T2D in Sweden who initiated second-line treatment with insulin or DPP-4i after metformin monotherapy during 2007–2014 identified ...
15 CitationsSource
#1Hertzel C. Gerstein (McMaster University)H-Index: 93
#2Jackie Bosch (McMaster University)H-Index: 45
Last. Salim Yusuf Mb Bs DPhil Frcpc (McMaster University)H-Index: 214
view all 12 authors...
BACKGROUND: The provision of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular events, but such a possibility has not been formally tested. METHODS: We randomly assigned 12,537 people (mean age, 63.5 years) with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes to receive insulin glargine (with a target fasting blood glucose level of ≤95 mg per deciliter [5.3 mmol per liter]) or standard care and ...
932 CitationsSource
Cited By14
#1Navin Kumar (Yale University)H-Index: 2
#2Jessica Ainooson (Yale University)
Last. Amy Zhang (Yale University)H-Index: 1
view all 9 authors...
BACKGROUND: Tobacco consumption is the leading cause of preventable death globally. The global mortality burden of tobacco use lies predominantly in low- to middle-income countries (LMICs). There is much evidence on the effectiveness of tobacco cessation RCTs in high-income nations. However, the evidence base in LMICs is far more limited. To effectively design randomized controlled trials (RCTs) that mitigate tobacco-related harms in LMICs, further understanding of RCTs in this environment will ...
#1Tomas Ganz (UCLA: University of California, Los Angeles)H-Index: 126
#2George R. AronoffH-Index: 20
Last. Jay B. Wish (Indiana University Health)H-Index: 14
view all 9 authors...
Abstract Patients with chronic kidney disease (CKD) are at increased risk of infection, attributable to immune dysfunction, increased exposure to infectious agents, loss of cutaneous barriers, comorbid conditions, and treatment-related factors (eg, hemodialysis [HD], immunosuppressant therapy). Because iron plays a vital role in pathogen reproduction and host immunity, it is biologically plausible that intravenous iron therapy and/or iron deficiency influence infection risk in CKD. Available dat...
#1William G. Herrington (University of Oxford)H-Index: 18
#2Natalie Staplin (Clinical Trial Service Unit)H-Index: 12
Last. Richard Haynes (University of Oxford)H-Index: 17
view all 3 authors...
Compared to other specialties, nephrology has reported relatively few clinical trials, and most of these are too small to detect moderate treatment effects. Consequently, interventions that are commonly used by nephrologists have not been adequately tested and some may be ineffective or harmful. More randomized trials are urgently needed to address important clinical questions in patients with kidney disease. The use of robust surrogate markers may accelerate early-phase drug development. Howeve...
1 CitationsSource
#1M. Angelyn Bethel (University of Oxford)H-Index: 23
#1M. Angelyn BethelH-Index: 15
Last. Peter ÖhmanH-Index: 11
view all 14 authors...
Background: The EXenatide Study of Cardiovascular Event Lowering (EXSCEL) assessed the impact of once-weekly exenatide 2 mg versus placebo in patients with type 2 diabetes, while aiming for glycemi...
#1Mario Luca Morieri (UNIPD: University of Padua)H-Index: 1
#2Mauro RigatoH-Index: 11
Last. Gian Paolo Fadini (UNIPD: University of Padua)H-Index: 47
view all 10 authors...
Abstract Introduction and aim Real-word data on the head-to-head comparisons among glucagon-like peptide-1 receptor agonists (GLP-1RA) are scant. Therefore, we aimed to compare the effectiveness of dulaglutide versus liraglutide and exenatide once weekly (exeOW) in type 2 diabetic (T2D) patients under routine care. Methods This was a retrospective, multicenter, real-world study on patients with T2D (aged 18–80) initiating a GLP-1RA between 2010 and 2018 at specialist outpatient clinics. We compa...
1 CitationsSource
#1Javier CortesH-Index: 49
#1Javier CortesH-Index: 12
Last. Nadia Harbeck (LMU: Ludwig Maximilian University of Munich)H-Index: 60
view all 16 authors...
Globally, cancer is the second leading cause of death, with numbers greatly exceeding those for human immunodeficiency virus/acquired immunodeficiency syndrome, tuberculosis, and malaria combined. Limited access to timely diagnosis, to affordable, effective treatment, and to high-quality care are just some of the factors that lead to disparities in cancer survival between countries and within countries. In this article, the authors consider various factors that prevent access to cancer medicines...
1 CitationsSource
#1Louise Bowman (University of Oxford)H-Index: 18
#2Aris Baras (Regeneron)H-Index: 14
Last. Evan D. Muse (Scripps Health)H-Index: 17
view all 14 authors...
The availability of large datasets from multiple sources [e.g. registries, biobanks, electronic health records (EHRs), claims or billing databases, implantable devices, wearable sensors, and mobile apps], coupled with advances in computing and analytic technologies, have provided new opportunities for conducting innovative health research. Equally, improved digital access to health information has facilitated the conduct of efficient randomized controlled trials (RCTs) upon which clinical manage...
3 CitationsSource
#1Abhinav Sharma (Stanford University)H-Index: 12
#2Neha J. Pagidipati (Duke University)H-Index: 11
Last. Rury R. Holman (University of Oxford)H-Index: 99
view all 21 authors...
Responding to concerns about the potential for increased risk of adverse cardiovascular (CV) outcomes, specifically myocardial infarction, associated with certain glucose-lowering therapies, the U....
2 CitationsSource
#1Marion Bennie (Strathclyde Institute of Pharmacy and Biomedical Sciences)H-Index: 22
#2William MalcolmH-Index: 7
Last. Tanja Mueller (Strathclyde Institute of Pharmacy and Biomedical Sciences)H-Index: 3
view all 4 authors...
Medicines are a major component of modern healthcare delivery, both in resource consumption and as drivers of innovation. The ever increasing application of digitalisation within day-to-day living and as part of our healthcare systems – with the resultant data generation – presents the opportunity to better define the populations exposed to medicines, and their benefits and harm in real world settings. This article outlines the development of the Scottish National Prescribing Information System ...
AIM: To evaluate the generalizability of cardiovascular outcome trials (CVOTs) on glucagon-like peptide-1 receptor agonists (GLP-1RAs), we assessed what proportion of real-world patients with type 2 diabetes (T2D) constitute true CVOT-like populations. MATERIALS AND METHODS: We applied inclusion/exclusion (I/E) criteria of each GLP-1RA CVOT to a cross-sectional database of 281 380 T2D patients from Italian diabetes outpatient clinics. We calculated the proportion of patients eligible for each CV...
1 CitationsSource